|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
1.The crucial role played by the renin-angiotensin-aldosterone system in the cardiovascular system and the immense therapeutic potential of angiotensin-converting enzyme inhibitors and, more recently, angiotensin II receptor blocking agents, in both heart failure and post-myocardial infarction is becoming increasingly evident.
|
9486084 |
1997 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
: This study suggests that ACE I/D polymorphism might represent a predisposing factor to severe heart failure, independently of well-known prognostic markers.
|
19050458 |
2008 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Heart failure recurred after viral infection but responded well to diuretics and angiotensin-converting enzyme inhibitors.
|
18261911 |
2008 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Heart failure (HF) is associated with many hospital admissions and relatively high mortality, rates decreasing with administration of beta-blockers (BBs), angiotensin-converting-enzyme inhibitors, angiotensin II receptor blockers, and mineralocorticoid receptor antagonists.
|
29154427 |
2017 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
ACE inhibitors are recognised as being highly effective therapy for hypertension and cardiac insufficiency, and have a more beneficial effect on survival rate than expected on the basis of known mechanisms of action.
|
12076180 |
2002 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Angiotensin-converting enzyme genotype modulates pulmonary function and exercise capacity in treated patients with congestive stable heart failure.
|
12356632 |
2002 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Angiotensin-converting enzyme-deletion (DD) polymorphism has been shown to influence beta-blocker therapy in heart failure.
|
12476935 |
2002 |
|
Heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Angiotensin converting enzyme inhibitors attenuated the expression of G-protein coupled receptor kinases in heart failure patients.
|
16501306 |
2006 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Angiotensin-converting enzyme (ACE) inhibitors improve the prognosis in mild, moderate and severe heart failure, as well as preventing the onset of heart failure in patients with chronic asymptomatic left-ventricular dysfunction and in those with reduced ejection fraction after myocardial infarction (MI).
|
17094051 |
2006 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
ACE gene deletion polymorphism may be operative in response to medical treatment that included ACE inhibitors in patients with HF.
|
18516385 |
2008 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Angiotensin-converting enzyme (ACE) inhibitors and β-adrenoceptor antagonists (β-blockers) are medications that are important in the management of hypertension and heart failure.
|
23579966 |
2013 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
ACE inhibitors are well tolerated drugs used in the treatment of hypertension and heart failure and would also treat antisocial behavior disorders.
|
23891037 |
2013 |
|
Heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
ACE and ACE2 expression at the mRNA and protein levels are significantly increased in the myocardium of patients with heart failure.
|
25869724 |
2015 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
ACE-Inhibition Benefit on Lung Function in Heart Failure is Modulated by ACE Insertion/Deletion Polymorphism.
|
26847573 |
2016 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Angiotensin-converting enzyme (ACE) inhibitors (ACEis) are beneficial in patients with heart failure, yet their role after heart transplantation (HTx) remains ambiguous.
|
27773450 |
2017 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Angiotensin-converting enzyme inhibitors (ACEi) and mineralocorticoid receptor (MR) antagonists are FDA-approved drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) and are used to treat heart failure.
|
27881412 |
2017 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Angiotensin-converting enzyme inhibitors and β-blockers are recommended first-line agents for heart failure.
|
27893331 |
2017 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blockers (ARB) were administered in 68.9% of HF discharged patients, beta-blockers in 84.8%, mineralocorticoid receptor antagonist (MRA) in 57.9%, diuretics in 85.9%, and digoxin in 23%.
|
28353316 |
2017 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Angiotensin converting enzyme inhibitors (ACE-I), are beneficial both in heart failure with reduced ejection fraction (HF-REF) and after myocardial infarction (MI).
|
28577679 |
2017 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
ACE/ACE-2 balance seems to determine the decompensation of HF in this model.
|
28970203 |
2018 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs), β blockers, and mineralocorticoid receptor antagonists (MRAs) are of proven benefit and are recommended by guidelines for management of patients with heart failure and reduced ejection fraction (HFrEF).
|
30103979 |
2018 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Angiotensin-converting enzyme inhibitor/angiotensin receptor blocker therapy reduced the odds of heart failure events by 29% (0.71, 0.61 to 0.83, P<0.001; I<sup>2</sup>=0%, P=0.78).
|
30296880 |
2019 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (ACEIs-ARBs) improve outcomes in heart failure (HF).
|
30299270 |
2018 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers have been the cornerstone for the treatment of heart failure (HF) with reduced ejection fraction for decades.
|
30345485 |
2019 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Angiotensin-converting enzyme inhibitors were more protective in the advancement and/or hospitalization of the hypertensive patient for heart failure than angiotensin receptor blockers.
|
30518809 |
2019 |